Sexually Transmitted Infections

STIs demand our attention

STIs in the U.S. reached an all-time high for the 6th consecutive year with 26.2 million new cases, resulting in 1 in 5 people in the US having an STI.1 This case volume is further complicated by the fact that many STIs present similar symptoms but require different treatments. This diagnostic challenge poses a serious threat to women’s health: upper genital tract infections, infertility, chronic pelvic pain, cervical cancer, and chronic infection with hepatitis viruses and HIV are just a few of the long-term implications of an untreated or persistent STI.2
Estimated prevalence of STIs in the United States (2013)1
Not to scale.

Better testing protects individuals and communities

  • Along with increased risk of serious complications, asymptomatic STIs increase the potential for sustained transmission in the community. Screening is a crucial measure for public as well as individual health.3
  • Because STI incidence is highest among adolescents and young adults, screening efforts focus on women between the age of 15-24 who identify as being sexually active.4
  • The CDC recommends Nucleic Acid Amplification Testing (NAAT) as the preferred method for accurate screening of patients.2,5,6

Hologic’s Offerings

Our broad array of highly sensitive NAATs lead the market in accurate detection of pathogens that are associated with STIs including chlamydia, gonorrhea, trichomoniasis, mycoplasma genitalium and herpes simplex virus.

Aptima Combo 2® CT/NG Test

Aptima® Trichomonas Vaginalis Test

Aptima® Mycoplasma Genitalium Test

Aptima® HSV 1 & 2 Test

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?

1. Centers for Disease Control and Prevention. Sexually Transmitted Disease Surveillance 2019. Atlanta: U.S. Department of Health and Human Services; 2021 2. Workowski, et al. Sexually Transmitted Infections Treatment Guidelines 2021. MMWR RecommRep 2021;70 3. Ghanem K. & Tuddenham S. Screening for sexually transmitted infections. UpToDate. Last updated April 21, 2020. Accessed August 20, 2021. 4. Owusu-Edusei K, et al. Cost- Effectiveness of Opt-Out Chlamydia Testing for High-Risk Young Women in the U.S. Am J Prev Med. 2016;51(2):216-24. doi:10.1016/j.amepre.2016.01.007. 5. CDC. Recommendations for the Laboratory-Based Detection of Chlamydia trachomatis and Neisseria gonorrhoeae. MMWR Recomm Rep. 2014;63(2). 6. ACOG. Vaginitis in Nonpregnant Patients. ACOG Practice Bulletin. Number 215. Obstet Gynecol. 2020;135(1):e1-e17. doi:10.1016/j.amepre.2016.01.007.